IRIS
MARTINI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 49.057
AS - Asia 142
SA - Sud America 99
NA - Nord America 16
AF - Africa 7
Totale 49.321
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 49.054
CN - Cina 80
BR - Brasile 79
VN - Vietnam 50
US - Stati Uniti d'America 15
AR - Argentina 8
ZA - Sudafrica 5
CO - Colombia 4
EC - Ecuador 4
ID - Indonesia 4
SG - Singapore 4
BD - Bangladesh 3
MA - Marocco 2
CL - Cile 1
GT - Guatemala 1
IN - India 1
MK - Macedonia 1
PE - Perù 1
PY - Paraguay 1
RU - Federazione Russa 1
UA - Ucraina 1
UY - Uruguay 1
Totale 49.321
Salva come PNG Salva come JPEG
Città #
Genova 32.879
Genoa 9.446
Rapallo 4.085
Vado Ligure 2.575
Bordighera 65
Beijing 42
Ho Chi Minh City 20
Ashburn 12
Hanoi 11
Da Nang 3
Guayaquil 3
Johannesburg 3
Porto Alegre 3
Santo André 3
São Paulo 3
Cape Town 2
Carapicuíba 2
Marrakesh 2
Milan 2
Phủ Lý 2
Ribeirão Preto 2
Rio de Janeiro 2
Rome 2
Sumaré 2
Abre Campo 1
Ahmedabad 1
Alfenas 1
Amarante 1
Araraquara 1
Araripe 1
Asunción 1
Barbacena 1
Barra de São Francisco 1
Belém 1
Biên Hòa 1
Bình Dương 1
Cachoeira do Sul 1
Camaragibe 1
Campinas 1
Canoas 1
Cao Lanh 1
Capitão Poço 1
Caxias 1
Caxias do Sul 1
Cerquilho 1
Conceição dos Ouros 1
Conselheiro Lafaiete 1
Criciúma 1
Córdoba 1
Des Moines 1
Dhaka 1
Embu das Artes 1
Extrema 1
Feira de Santana 1
Felixlândia 1
Fortaleza 1
Godoy Cruz 1
Goiana 1
Guarulhos 1
Guatemala City 1
Haiphong 1
Iguape 1
Inhapim 1
Ipu 1
Juiz de Fora 1
Lima 1
Lomas de Zamora 1
Mafra 1
Manaus 1
Mauá 1
Mirante da Serra 1
Mongaguá 1
Monte Alto 1
Montevideo 1
Morada Nova de Minas 1
Moscow 1
Neiva 1
Ninh Bình 1
Niterói 1
Nova Friburgo 1
Paracatu 1
Pereira 1
Pesqueira 1
Petrolina 1
Petrópolis 1
Pongaí 1
Pouso Alegre 1
Poços de Caldas 1
Quito 1
Rio Grande 1
Rio do Sul 1
Riohacha 1
Río Gallegos 1
San Antonio de Padua 1
San Cristóbal 1
San Salvador de Jujuy 1
Santa Fe 1
Santa Isabel 1
Santo Antônio de Pádua 1
Serang 1
Totale 49.247
Salva come PNG Salva come JPEG
Nome #
Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. 251
A longitudinal printo study on growth and puberty in juvenile systemic lupus erythematosus. 210
Novel automated system for Magnetic Resonance Imaging quantification of the inflamed synovial membrane volume in patients with juvenile idiopathic arthritis. 207
CD70 deficiency due to a novel mutation in a patient with severe chronic EBV infection presenting as a periodic fever 202
Malattia di Menetrier e gastropatia ipertrofica proteino-disperdente transitoria del bambino: due entità cliniche distinte? 198
ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study 188
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 185
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 182
HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. 176
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. 175
A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. 174
Parent and child acceptable symptom state in juvenile idiopathic arthritis. 174
Candidate Genes in Patients with Autoinflammatory Syndrome Resembling Tumor Necrosis Factor Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene 173
Delineating the application of ultrasound in detecting synovial abnormalities of subtalar joint in juvenile idiopathic arthritis 173
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. 168
Differentiating PFAPA syndrome from monogenic periodic fevers. 166
Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis. 164
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome 164
Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. 164
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative 164

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Assessment of Disease Activity in Patients with Juvenile Idiopathic Arthritis 163
Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. 162
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 161
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis 160
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis 160
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 159
Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. 159
Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference 159
A positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. 157
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 157
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial 156
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 153
HLA-DRB1∗11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis 153
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. 152
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 152
Advances in biomarkers for paediatric rheumatic diseases 152
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 151
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 150
A circulating reservoir of pathogenic-like CD4+ T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment 150
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report 149
Aortic valve regurgitation as the presenting sign of Takayasu arteritis. 149
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features 148
The role of imaging in juvenile idiopathic arthritis 148
Antiphospholipid antibody syndrome in pediatric patients. 147
Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. 146
The EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis, and childhood Takayasu arteritis: ankara 2008. part ii: final classification criteria. 145
Paediatric-onset systemic lupus erythematosus. 145
Development and initial validation of composite parent and child centered disease assessment indices for juvenile idiopathic arthritis. 145
High prevalence of antiphospholipid antibodies in children with idiopatic cerebral ischemia 144
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. 144
Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. 144
Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis. 144
Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients 144
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 144
Phenotypic and functional characterization of switch memory B cells from patients with oligoarticular juvenile idiopathic arthritis 143
Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases 143
Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations 143
Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: Clinical and therapeutic implications 143
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. 142
Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study 142
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 142
EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice 142
Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. 142
Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis 141
Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. 140
Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. 140
Prevalence of anticardiolipin antibodies in juvenile chronic arthritis. 140
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis 140
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. 140
Adapted versions of the Sharp-van Der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis 139
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis 139
Chronic recurrent multifocal osteomyelitis with unusual features. 139
Recurrent pericarditis in Myhre syndrome. 139
Tolerance and auto-immunity: 50 years after burnet. 138
In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6 transgenic mice with a hIL-6 receptor antagonist 138
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. 138
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. 138
Antinuclear antibody positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. 137
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis. 137
Preliminary definition of improvement in juvenile arthritis. 137
A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children 137
Chemokine receptor CCR7 is expressed in muscle fibers in juvenile dermatomyositis 137
A randomized, double-blind, placebo-controlled trial of paracetamol and ketoprofren lysine salt for pain control in children with pharyngotonsillitis cared by family pediatricians 137
Cryopyrin-associated periodic syndromes in Italian Patients: Evaluation of the rate of somatic NLRP3 mosaicism and phenotypic characterization 137
Chronic intoxication by ethane-1-hydroxy-1,1-diphosphonate (EHDP) in a child with myositis ossificans progressiva. 136
Responsiveness of outcome measures in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. 136
Criteria to define response to therapy in paediatric rheumatic diseases. 135
A new short and simple health-related quality of life measure for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis 135
Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 135
The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. 135
Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. 135
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis. 135
Performing trials in children with rheumatic diseases: Comment on the editorial by Lehman 134
Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. 134
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 133
Advances from clinical trials in juvenile idiopathic arthritis. 133
A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry 133
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 133
Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis 133
Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease 132
Totale 15.147
Salva come PNG Salva come JPEG
Categoria #
all - tutte 164.039
article - articoli 162.044
book - libri 0
conference - conferenze 270
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.725
Totale 328.078
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.036 0 0 0 0 167 284 140 275 298 365 221 286
2021/20225.624 171 429 630 450 325 240 443 1.291 206 454 331 654
2022/20234.958 551 245 44 421 850 978 23 467 921 33 347 78
2023/20242.130 147 374 45 211 197 346 117 134 96 53 105 305
2024/20256.182 98 575 248 385 819 677 545 876 310 361 502 786
2025/20263.177 1.203 406 625 925 18 0 0 0 0 0 0 0
Totale 49.893